Key points from article :
Scientists find a way to reduce toxicity of a cancer drug that is potentially a senolytic.
Navitoclax (ABT263) which works by inhibiting B-cell lymphoma 2 pathway is a cancer drug.
But using too much navitoclax increase the risk of decreasing platelets.
Can use a proteolysis-targeting chimera (PROTAC) to convert the navitoclax into PZ15227.
PZ15227 is less toxic and only inhibits Bcl-xl, which is more relevant to senescent cells.
So it also increases effectiveness against senescent cells.
Lead to rejuvenation of tissue stem and progenitor cells in aged mice.
